ABBVAbbVieSigning up patients
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 680 (planned)
- Started
- Jan 8, 2026
- Main results expected
- Mar 2041
- Fully finished
- Jan 2042
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 2 and 3: Percentage of Participants with Adverse Events (AE)s
Measured over: Up to Approximately 16 Years
Phase 2: Change in Clinical Activity
Measured over: Up to Approximately 52 weeks
Phase 3: Minimal Residual Disease (MRD) Negative CR Rate
Measured over: Up to Approximately 52 weeks
Phase 3: Progression-Free Survival (PFS)
Measured over: Up to Approximately 130 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07095452 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC